Iltamiocel

Summary

Iltamiocel (CHEMBL4650237) is a phase-3 clinical-stage cell; indicated across 5 conditions including myocardial ischemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 5 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4650237
Name	Iltamiocel
Type	Cell
Max phase	3

Also known as: AMDC, AMDC-USR, Iltamiocel, ILTAMIOCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
myocardial ischemia	1	MONDO:0024644	EFO:1001375

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	5
PHASE1/PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03104517	PHASE3	ACTIVE_NOT_RECRUITING	Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
NCT05776277	PHASE3	ACTIVE_NOT_RECRUITING	Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
NCT01382602	PHASE3	COMPLETED	Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
NCT01893138	PHASE3	COMPLETED	Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
NCT03997318	PHASE3	WITHDRAWN	Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)
NCT01353690	PHASE1/PHASE2	TERMINATED	Autologous Cell Therapy for Ischemic Heart Failure
NCT01600755	PHASE1/PHASE2	COMPLETED	Autologous Cell Therapy for Treatment of Fecal Incontinence
NCT06743620	Not specified	ENROLLING_BY_INVITATION	Observational Registry for Iltamiocel Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).